Fresenius buys rights to RenalTech's BetaSorb:
This article was originally published in Clinica
Executive Summary
Fresenius Medical Care has bought exclusive North American distribution rights to RenalTech's BetaSorb device as an accessory to hemodialysis. Fresenius and RenalTech expect to announce a similar agreement for international markets this week. Fresenius will carry out multicentre outcome studies of the device, which is based on RenalTech's adsorbent polymer technology for blood detoxification, once US and EU regulatory approval is granted. Fresenius will also make a series of equity investments in the New York-based company in the form of upfront and milestone payments.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.